Featuring an interview with Dr Joshua Sabari, including the following topics:
- Updates in the use of adjuvant targeted therapy for localized and metastatic non-small cell lung cancer (NSCLC); impact of the ADAURA trial (0:00)
- Factors in the selection of second-line therapy for patients with and without driver mutations (10:30)
- Role of immunotherapy for patients with driver mutations (14:26)
- Recent updates in the use of antibody-drug conjugates for NSCLC (17:01)
- Combining VEGF inhibition with other therapies for previously treated NSCLC (20:10)
- Factors affecting response to immunotherapy in patients with lung cancer (23:19)
CME information and select publications